TAS-118联合奥沙利铂对比S-1联合顺铂一线治疗晚期胃癌的III期随机对照研究(SOLAR)
SOLAR研究是一项在日本和韩国62个中心开展的随机、开放标签、III期试验,比较TAS-118(S-1+亚叶酸钙)联合奥沙利铂与S-1联合顺铂一线治疗HER2阴性晚期胃癌的疗效与安全性。共随机711例患者,主要终点分析集为TAS-118+奥沙利铂组347例和S-1+顺铂组334例。
要点
- TAS-118联合奥沙利铂组周围感觉神经病变(≥3级)发生率高于对照组(9% vs <1%)。
- TAS-118联合奥沙利铂可作为亚洲晚期胃癌患者的新一线治疗选择。
核心结论
- 在亚洲HER2阴性晚期胃癌患者中,TAS-118联合奥沙利铂一线治疗较S-1联合顺铂显著改善总生存期,具有临床意义的疗效提升。
研究设计与样本
- 随机、开放标签、III期试验,在日本和韩国62个中心开展,共随机711例患者(TAS-118+奥沙利铂组356例,S-1+顺铂组355例)。
- 主要终点分析排除11例未治疗和19例不合格患者后,TAS-118+奥沙利铂组347例,S-1+顺铂组334例。
- 患者为20岁及以上、组织学确诊的晚期胃癌、HER2阴性或未知、ECOG PS 0-1、有可测量或可评估转移灶且未经治疗。
主要发现
- TAS-118+奥沙利铂组(352例)≥3级不良事件常见:贫血16%、中性粒细胞减少15%、食欲减退15%、腹泻9%、周围感觉神经病变9%。
- S-1+顺铂组(348例)≥3级不良事件常见:贫血18%、中性粒细胞减少25%、食欲减退13%、腹泻4%、周围感觉神经病变<1%。
- 严重不良事件发生率:TAS-118+奥沙利铂组44%(155/352),S-1+顺铂组46%(159/348)。
- TAS-118+奥沙利铂组发生2例治疗相关死亡(肺结核和病毒性肺炎)。
临床怎么用
- 对于HER2阴性晚期胃癌亚洲患者,可考虑TAS-118联合奥沙利铂作为新的一线治疗选择。
- 用药时需关注周围感觉神经病变和腹泻等不良反应,TAS-118+奥沙利铂组神经病变发生率较高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: S-1 plus leucovorin and oxaliplatin showed promising efficacy for treatment of advanced gastric cancer in a randomised phase 2 study. We aimed to evaluate the efficacy and safety of oral TAS-118 (S-1 plus leucovorin) and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer. METHODS: We did a randomised, open-label, phase 3 trial in 62 centres across Japan and South Korea. Patients aged 20 years or older, with a histologically confirmed advanced gastric cancer with negative or unknown HER2 status, with Eastern Cooperative Oncology Group performance status of 0 or 1, measurable or evaluable metastatic lesions, and no previous treatment were randomly assigned (1:1) via an interactive web response system using the minimisation method, stratified by performance status, presence of a measurable lesion, and country, to receive TAS-118 (S-1 40-60 mg and leucovorin 25 mg orally twice daily for 7 days) plus oxaliplatin (85 mg/m2 intravenously on day 1) every 2 weeks, or S-1 (40-60 mg orally twice daily) for 21 days plus cisplatin (60 mg/m2 intravenously on day 1 or 8) every 5 weeks. The primary endpoint was overall survival in patients who had advanced gastric cancer with measurable or evaluable metastatic lesions and who received the study drug. Safety was assessed in all patients who received the study drug. This study was registered at ClinicalTrials.gov, NCT02322593. FINDINGS: Between Jan 28, 2015, and Dec 5, 2016, 711 patients were randomised to TAS-118 plus oxaliplatin (n=356) or S-1 plus cisplatin (n=355). 11 untreated patients and 19 ineligible patients were excluded from the primary analysis (TAS-118 plus oxaliplatin group n=347, S-1 plus cisplatin group n=334) following recommendation from the independent data monitoring committee. After median follow-up of 26·0 months (IQR 22·0-32·8), median overall survival was 16·0 months (95% CI 13·8-18·3) in the TAS-118 plus oxaliplatin group and 15·1 months (95% CI 13·6-16·4) in the S-1 plus cisplatin group (hazard ratio 0·83, 95% CI 0·69-0·99; p=0·039). The most common grade 3 or higher adverse events in the 352 patients in the TAS-118 plus oxaliplatin group and the 348 patients in the S-1 plus cisplatin group were anaemia (56 [16%] vs 64 [18%]), neutropenia (54 [15%] vs 88 [25%]), decreased appetite (53 [15%] vs 46 [13%]), diarrhoea (33 [9%] vs 15 [4%]), and peripheral sensory neuropathy (30 [9%] vs one [<1%]). Serious adverse events were observed in 155 (44%) of 352 patients in the TAS-118 plus oxaliplatin group and 159 (46%) of 348 patients in the S-1 plus cisplatin group. Two treatment-related deaths occurred in the TAS-118 plus oxaliplatin group (pulmonary tuberculosis and viral pneumonia). INTERPRETATION: TAS-118 plus oxaliplatin showed a clinically meaningful improvement in efficacy compared with S-1 plus cisplatin, and could be considered a new first-line treatment option for advanced gastric cancer in Asian patients. FUNDING: Taiho Pharmaceutical and Yakult Honsha.
引用
- Kang YK, Chin K, Chung HC, et al. S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial. Lancet Oncol. 2020. PMID: 32682457. doi:10.1016/S1470-2045(20)30315-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。